Clinical importance of GVL mismatch combinations in HLA-DPB1 mismatch
| All diseases . | n . | Acute GVHD . | Relapse . | OS* . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| HLA-DPB1 matched | 864 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 808 | 1.34 (1.03-1.74) | .028 | 0.83 (0.68-1.01) | 0068 | 0.96 (0.83-1.12) | .62 |
| GVL mismatch combination | 258 | 1.18 (0.81-1.73) | .375 | 0.47 (0.33-0.67) | <.001 | 0.75 (0.59-0.94) | .012 |
| ALL | |||||||
| HLA-DPB1 matched | 250 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 263 | 1.56 (0.96-2.54) | .067 | 0.85 (0.6-1.19) | .33 | 1.10 (0.85-1.43) | .48 |
| GVL mismatch combination | 80 | 1.27 (0.63-2.57) | .5 | 0.75 (0.45-1.26) | .28 | 0.95 (0.65-1.39) | .8 |
| AML | |||||||
| HLA-DPB1 matched | 308 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 264 | 1.47 (0.9-2.39) | .13 | 0.83 (0.61-1.14) | .26 | 0.95 (0.74-1.23) | .72 |
| GVL mismatch combination | 89 | 1.25 (0.62-2.5) | .54 | 0.44 (0.24-0.78) | .006 | 0.71 (0.48-1.06) | .1 |
| CML | |||||||
| HLA-DPB1 matched | 176 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 162 | 1.25 (0.74-2.14) | .41 | 0.69 (0.40-1.20) | .19 | 0.93 (0.65-1.33) | .69 |
| GVL mismatch combination | 54 | 1.13 (0.51-2.47) | .66 | 0.14 (0.03-0.55) | .005 | 0.50 (0.25-0.98) | .041 |
| All diseases . | n . | Acute GVHD . | Relapse . | OS* . | |||
|---|---|---|---|---|---|---|---|
| HR (95% CI) . | HR (95% CI) . | P . | HR (95% CI) . | P . | |||
| HLA-DPB1 matched | 864 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 808 | 1.34 (1.03-1.74) | .028 | 0.83 (0.68-1.01) | 0068 | 0.96 (0.83-1.12) | .62 |
| GVL mismatch combination | 258 | 1.18 (0.81-1.73) | .375 | 0.47 (0.33-0.67) | <.001 | 0.75 (0.59-0.94) | .012 |
| ALL | |||||||
| HLA-DPB1 matched | 250 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 263 | 1.56 (0.96-2.54) | .067 | 0.85 (0.6-1.19) | .33 | 1.10 (0.85-1.43) | .48 |
| GVL mismatch combination | 80 | 1.27 (0.63-2.57) | .5 | 0.75 (0.45-1.26) | .28 | 0.95 (0.65-1.39) | .8 |
| AML | |||||||
| HLA-DPB1 matched | 308 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 264 | 1.47 (0.9-2.39) | .13 | 0.83 (0.61-1.14) | .26 | 0.95 (0.74-1.23) | .72 |
| GVL mismatch combination | 89 | 1.25 (0.62-2.5) | .54 | 0.44 (0.24-0.78) | .006 | 0.71 (0.48-1.06) | .1 |
| CML | |||||||
| HLA-DPB1 matched | 176 | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | |||
| HLA-DPB1 1 allele mismatched | 162 | 1.25 (0.74-2.14) | .41 | 0.69 (0.40-1.20) | .19 | 0.93 (0.65-1.33) | .69 |
| GVL mismatch combination | 54 | 1.13 (0.51-2.47) | .66 | 0.14 (0.03-0.55) | .005 | 0.50 (0.25-0.98) | .041 |
Each group was compared with the HLA-DPB1 matched group. Confounders considered were sex (donor-recipient pairs), patient age (linear), donor age (linear), type of disease, risk of leukemia relapse (standard, high, and diseases other than leukemia), GVHD prophylaxis (CSP vs FK), ATG vs no ATG), and preconditioning (TBI vs non-TBI).
ref indicates reference.
The HR indicates the likelihood that OS will be shorter (if HR > 1) or longer (HR < 1) than when the HLA type matches (ie, the Ref condition).